Posted by Michael Wonder on 17 May 2021
Sandoz Canada launches its 6th biosimilar with Inclunox and Inclunox HP (enoxaparin sodium solution for injection 100 mg/mL and 150 mg/mL (high potency))
17 May 2021 - New Sandoz biosimilar launch can potentially lower healthcare costs, especially for Canadian hospitals, as 75% of the distribution/administration of this drug in Canada is through hospital settings.
Sandoz Canada announced today the launch of PrInclunox and PrInclunox HP (enoxaparin sodium solution for injection, reference biologic drug: Sanofi’s PrLovenox and PrLovenox HP), which was authorised for sale in Canada by Health Canada on 5 November 2020.
